

TABLE OF CONTENTS

Antidepressants	2	Comparison of Long-Acting IM Antipsychotics	223	Cannabinoids	401
Selective Serotonin Reuptake Inhibitors (SSRIs)	3	Switching Antipsychotics	230	Psychedelics and Dissociative Drugs	404
Norepinephrine Dopamine Reuptake Inhibitor (NDRI)	18	Antipsychotic Augmentation Strategies	232	Opioids	410
Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)	24	Antipsychotic-Induced Extrapyramidal Side Effects and Their Management	236	Inhalants/Aerosols	414
Serotonin-2 Antagonists/Reuptake Inhibitors (SARIs)	34	Extrapyramidal Adverse Effects of Antipsychotics	236	Gamma-hydroxybutyrate (GHB)/Sodium Oxybate	416
Serotonin-1A Partial Agonist/Serotonin Reuptake Inhibitor (SPARI)	40	Treatment Options for Extrapyramidal Side Effects	240	Flunitrazepam (Rohypnol)	418
Serotonin Modulator and Stimulator (SMS)	45	Effects on Acute Extrapyramidal Side Effects and Tardive Dyskinesia	246	Nicotine/Tobacco	419
Noradrenergic/Specific Serotonergic Antidepressant (NaSSA)	49	Comparison of Agents for Treating Acute Extrapyramidal Side Effects and Tardive Dyskinesia	246	Treatment of Substance Use Disorders	422
Nonselective Cyclic Antidepressants	54	Doses and Pharmacokinetics of Agents for Treating Acute Extrapyramidal Side Effects and Tardive Dyskinesia	248	Acamprosate	424
Monoamine Oxidase Inhibitors	62	Anxiolytic (Antianxiety) Agents	252	Disulfiram	426
Reversible Inhibitor of MAO-A (RIMA)	63	Benzodiazepines	252	Naltrexone	429
Irreversible Monoamine Oxidase (A&B) Inhibitors (MAOIs)	66	Comparison of the Benzodiazepines	261	Buprenorphine	433
Irreversible MAO-B Inhibitor	73	Buspirone	265	Methadone	437
Selective Serotonin 5-HT _{1A} Receptor Agonist	77	Hypnotics/Sedatives	269	Pharmacotherapy for Nicotine/Tobacco Use Disorder	444
GABA _A Receptor Positive Modulators	80	Comparison of Hypnotics/Sedatives	276	Comparison of Treatments for Nicotine/Tobacco Use Disorder	446
NMDA Receptor Antagonists	86	Mood Stabilizers	283	Unapproved Treatments of Psychiatric Disorders	450
NMDA Receptor Antagonist/CYP2D6 Inhibitor	95	Lithium	283	Adrenergic Agents	451
Effects of Antidepressants on Neurotransmitters/Receptors	100	Anticonvulsants	294	Anti-inflammatory Agents	454
Pharmacological Effects of Antidepressants on Neurotransmitters/Receptors	101	Comparison of Anticonvulsants	313	Cannabinoids	460
Frequency of Adverse Reactions to Antidepressants at Therapeutic Doses	102	Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic Doses	320	Dopaminergic Agents	461
Antidepressant Doses and Pharmacokinetics	105	Drugs for ADHD	322	GABA Agents/Anticonvulsants	463
Difficult-to-Treat Depression (DTD)	109	Psychostimulants	322	Hormones	465
Electroconvulsive Therapy (ECT)	116	Selective Norepinephrine Reuptake Inhibitors	333	NMDA Agents (Glutamatergic Modulators)	470
Bright Light Therapy (BLT)	124	α ₂ agonists	339	5-HT ₃ Antagonists	472
Repetitive Transcranial Magnetic Stimulation (rTMS)	129	Comparison of Drugs for ADHD	343	Miscellaneous	473
Antipsychotics	134	Augmentation Strategies in ADHD	355	Natural Health Products	476
First-Generation Antipsychotics/FGAs	139	Drugs for Treatment of Dementia	359	Ginkgo Biloba	476
Second-Generation Antipsychotics/SGAs	157	Cholinesterase Inhibitors	359	Kava Kava	478
Third-Generation Antipsychotics/TGAs	185	Memantine	366	Melatonin	479
5-HT _{2A} Inverse Agonist Antipsychotic	199	Amyloid Beta-Directed Antibodies	369	Omega-3 Polyunsaturated Fatty Acids	481
Muscarinic Agonist/Antagonist Antipsychotic	201	Comparison of Drugs for Treatment of Dementia	376	S-Adenosyl-L-Methionine (SAME)	484
Effects of Antipsychotics on Neurotransmitters/Receptors	205	Sex-Drive Depressants	382	St. John's Wort	485
Pharmacological Effects of Antipsychotics on Neurotransmitters/Receptor Subtypes	206	Comparison of Sex-Drive Depressants	385	Valerian	486
Relative Tolerability Profiles of Antipsychotics	207	Drugs of Abuse	390	Vitamins	488
Frequency (%) of Adverse Reactions to Antipsychotics at Therapeutic Doses	209	Alcohol	392	Pharmacogenetic Information for Common Psychotropic Drugs	491
Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting Injections)	212	Stimulants	396	Pharmacogenetic Effects	491
				Glossary	495
				Drug Use in Pregnancy and Effects on Breast Milk	499
				Patient Information Sheets	501
				Index of Drugs	502